共查询到5条相似文献,搜索用时 0 毫秒
1.
Hye‐soon Kim Doo‐man Kim Bong‐soo Cha Tae Sun Park Kyoung‐ah Kim Dong‐lim Kim Choon Hee Chung Jeong‐hyun Park Hak Chul Jang Dong‐seop Choi 《Journal of diabetes investigation.》2014,5(6):701-708
Aims/Introduction
To compare the efficacy and safety of early combination therapy with glimepiride/metformin to metformin uptitration in reducing glycated hemoglobin (HbA1c) levels in Korean type 2 diabetic patients inadequately controlled on low-dose metformin monotherapy.Materials and Methods
In a randomized, open label, parallel group, multicenter study, 209 Korean type 2 diabetic patients (HbA1c 7.0–10.0%, on metformin 500–1,000 mg/day) received glimepiride/metformin fixed-dose combination (G/M FDC) or metformin uptitration treatment (Met UP). The primary end-point was the change in HbA1c from baseline to week 24.Results
G/M FDC therapy provided significantly greater adjusted mean decreases vs Met UP therapy in HbA1c (−1.2 vs −0.8%, P < 0.0001), and fasting plasma glucose (−35.7 vs −18.6 mg/dL, P < 0.0001). A significantly greater proportion of patients with G/M FDC therapy achieved HbA1c < 7% (74.7 vs 46.6%, P < 0.0001) at the end of the study. More patients experienced hypoglycemia with G/M FDC therapy compared with Met UP therapy (41 vs 5.6%, P < 0.0001), but there was no serious hypoglycemia in any group. A modest increase in mean bodyweight occurred in the patients who were treated with G/M FDC therapy (1.0 kg), whereas a slight decrease was observed in the patients who were treated with Met UP therapy (−0.7 kg).Conclusion
The present study showed that glimepiride/metformin fixed-dose combination therapy was more effective in glycemic control than metformin uptitration, and was well tolerated in type 2 diabetic patients inadequately controlled by low-dose metformin monotherapy in Korea. This trial was registered with ClinicalTrial.gov (no. ). NCT00612144相似文献2.
3.
Dipeptidyl peptidase‐4 inhibitors as preferable oral hypoglycemic agents in terms of treatment satisfaction: Results from a multicenter, 12‐week,open label,randomized controlled study in Japan (PREFERENCE 4 study) 下载免费PDF全文
Hitoshi Ishii Yasuaki Hayashino Yasuhiro Akai Matahiro Yabuta Satoru Tsujii 《Journal of diabetes investigation.》2018,9(1):137-145
4.
Huyen Tran Tim Brighton Andrew Grigg Simon McRae Joanna Dixon Daniel Thurley Maher K. Gandhi Matt Truman Paula Marlton John Catalano 《British journal of haematology》2014,167(2):243-251
The efficacy of a fixed‐dose rituximab schedule was prospectively explored in primary/acute refractory, relapsed or chronic (platelet count >10 × 109/l and ≤50 × 109/l) idiopathic thrombocytopenic purpura (ITP). Patients received two doses of rituximab (1000 mg) on days 1 and 15 and were followed‐up on weeks 1–8, 12, 26, 39 and 52. A total of 122 patients were included in the safety population; efficacy was analysed in 108 patients. Overall response rate (ORR) at week 8, defined as the proportion of patients achieving complete response (CR; platelet count >150 × 109/l) or partial response (PR; platelet count >50 × 109/l) was 44%. Therapeutic response, defined as achieving a response at week 8, with at least a minor response (MR; platelet count >30 × 109/l), sustained up to weeks 26 and 52 and accompanied by a reduction in ITP medications, was achieved in 44% (week 26) and 35% (week 52) of patients, respectively. Treatment was well tolerated with no safety concerns. While this study failed to meet its primary endpoint of an ORR of 50%, the efficacy of two fixed doses of rituximab appear to provide similar efficacy to the standard 375 mg/m2 four‐dose schedule in relapsed/chronic ITP. 相似文献
5.
David E. Kandzari Dimitri Karmpaliotis Annapoorna S. Kini Jeffrey W. Moses Pradyumna E. Tummala J. Aaron Grantham Charles Orr William Lombardi William J. Nicholson Nicholas J. Lembo Jeffrey J. Popma Jin Wang Weiying Zhao Robert McGreevy 《Catheterization and cardiovascular interventions》2019,94(4):509-515